Elsevier Inc.

SHERPA: Unknown

People

  1. Abu-Rustum
    Abu-Rustum
  2. Chi
    Chi
  3. Lee
    Lee
  4. Giralt
    Giralt
  5. Mulhall
    Mulhall
  6. Perales
    Perales
  7. Sonoda
    Sonoda
  8. Leitao
    Leitao
  9. Wu
    Wu
  10. Wolden
    Wolden

Groups

  1. Department of Medicine (4609)
  2. Surgery (3545)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2650)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)
  7. Center for Hematologic Malignancies (1674)
  8. Hematologic Malignancies, Division of (1609)
  9. Gynecology Disease Management Team (1425)
  10. Sloan Kettering Institute Faculty (1413)
Search Within
Formats
  1. Journal Article (7391)
  2. Meeting Abstract (4693)
  3. Review (616)
  4. Book Section (538)
  5. Editorial (250)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4609)
  2. Surgery (3545)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2650)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (376)

More People

Years
  1. 2025 (243)
  2. 2024 (784)
  3. 2023 (762)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2610)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (969)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (524)
  6. Journal of Sexual Medicine (435)

More Publications

Results (13858)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interference for CD3+and CD19+subset enrichment by immunomagnetic beads
    Meeting Abstract

    Kim, E.; Tang, X.; Yeh, N.; Barone, J.; Ye, F.; Blouin, A. G.
    Human Immunology (2024)

    Fulltext@MSK | Save
  • Undetected mixed chimerism in myeloid subset enrichments by an immunomagnetic bead-based method
    Meeting Abstract

    McManus, P.; Hura, D.; Kim, B.; Kim, E.; Barone, J.; Ye, F.; Blouin, A. G.
    Human Immunology (2024)

    Fulltext@MSK | Save
  • Identification of a novel DQB1*03 allele in pseudo exon 5 by next generation sequencing HLA typing
    Meeting Abstract

    Yeh, N.; McManus, P.; Kim, B.; Kim, E.; Savchik, C.; Barone, J.; Blouin, A. G.; Ye, F.
    Human Immunology (2024)

    Fulltext@MSK | Save
  • Reducing new sample requests for high resolution HLA typing by next generation sequencing
    Meeting Abstract

    Barone, J.; Savchik, C.; Yeh, N.; McManus, P.; Kim, E.; Ye, F.; Blouin, A. G.
    Human Immunology (2024)

    Fulltext@MSK | Save
  • Characteristics of patients and management of ocular adverse events after treatment with belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma (RRMM): A real-world study in Europe
    Meeting Abstract

    Cavo, M.; Delforge, M.; Dimopoulos, M.; Escalante-Barrigon, F.; Hultcrantz, M.; Kleinman, D.; Lee, H.; Vij, R.; Greil, R.; Melchardt, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Daratumumab + bortezomib/lenalidomide/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: Results of the phase 3 CEPHEUS study
    Meeting Abstract

    Usmani, S. Z.; Facon, T.; Hungria, V.; Bahlis, N. J.; Venner, C. P.; Braunstein, M.; Pour, L.; Marti, J.; Basu, S.; Cohen, Y. C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence, timing, and management of infections in patients receiving daratumumab for the treatment of newly diagnosed transplant-ineligible multiple myeloma in the MAIA study
    Meeting Abstract

    Bahlis, N. J.; Facon, T.; Usmani, S.; Moreau, P.; Raje, N.; Zweegman, S.; Chari, A.; Perrot, A.; Manier, S.; Orlowski, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • MagnetisMM-30: A phase 1B, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Lesokhin, A.; Raza, M.; Acosta, J.; Mueller, P. Y.; O'Connell, A.; Yver, A.; Lou, C.; Finn, G.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Evaluation of the safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment
    Meeting Abstract

    Terpos, E.; Ntanasis-Stathopoulos, I.; Kyriakou, C.; Tan, C.; Abildgaard, N.; Delforge, M.; Fantl, D.; Usmani, S.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-eligible patients with multiple myeloma: A pooled analysis of patients aged ≥65 years from both PERSEUS and GRIFFIN studies
    Meeting Abstract

    Rodríguez-Otero, P.; Voorhees, P. M.; Boccadoro, M.; Laubach, J.; Einsele, H.; Sborov, D. W.; Dimopoulos, M.; Broijl, A.; Mina, R.; Spencer, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save